Novel Therapeutic Approaches of Pulmonary Arterial Hypertension

 

 Buy Article Permissions and Reprints

Abstract

Pulmonary arterial hypertension (PAH) is an uncommon disease characterized progressive remodeling of pulmonary vasculature. Although treatment for PAH have improved in last two decades but the outcome remains fatal. Currently, the therapies for PAH target three well-established pathways the nitric oxide (NO) pathway, endothelin receptors, and prostanoids. There are multiple potential targets for development of newer drugs in PAH which requires meticulous research and clinical trials.

• References

• 1 Hoeper MM, Humbert M, Souza R. , et al. A global view of pulmonary hypertension. Lancet Respir Med 2016; 4 (04) 306-322
  CrossrefPubMedGoogle Scholar
• 2 McLaughlin VV, Archer SL, Badesch DB. , et al; ACCF/AHA. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009; 119 (16) 2250-2294
  CrossrefPubMedGoogle Scholar
• 3 Simonneau G, Montani D, Celermajer DS. , et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53 (01) 1801913 [ https://doi.org/10.1183/13993003.01913-2018 ]
  Google Scholar
• 4 Bishop JM, Cross KW. Physiological variables and mortality in patients with various categories of chronic respiratory disease. Bull Eur Physiopathol Respir 1984; 20 (06) 495-500
  PubMedGoogle Scholar
• 5 Pepke-Zaba J, Delcroix M, Lang I. , et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 2011; 124 (18) 1973-1981
  CrossrefPubMedGoogle Scholar
• 6 Coghlan JG, Wolf M, Distler O. , et al. Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis. Eur Respir J 2018; 51 (04) 1701197
  CrossrefPubMedGoogle Scholar
• 7 Ghofrani HA, Galiè N, Grimminger F. , et al. PATENT-1 Study Group. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013; 369: 330-340
  CrossrefPubMedGoogle Scholar
• 8 Rubin LJ, Galiè N, Grimminger F. , et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J 2015; 45 (05) 1303-1313
  CrossrefPubMedGoogle Scholar
• 9 Galiè N, Ghofrani HA, Torbicki A. , et al; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353 (20) 2148-2157
  CrossrefPubMedGoogle Scholar
• 10 Galiè N, Brundage BH, Ghofrani HA. , et al; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119 (22) 2894-2903 Circulation 2011;124(10):e279
  CrossrefPubMedGoogle Scholar
• 11 Granton J, Langleben D, Kutryk MB. , et al. Endothelial NO-synthase gene-enhanced progenitor cell therapy for pulmonary arterial hypertension: the PHACeT trial. Circ Res 2015; 117 (07) 645-654
  CrossrefPubMedGoogle Scholar
• 12 Falcetti E, Hall SM, Phillips PG. , et al. Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 182 (09) 1161-1170
  CrossrefPubMedGoogle Scholar
• 13 Akagi S, Nakamura K, Matsubara H. , et al. Epoprostenol therapy for pulmonary arterial hypertension. Acta Med Okayama 2015; 69 (03) 129-136
  PubMedGoogle Scholar
• 14 Simonneau G, Barst RJ, Galie N. , et al; Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165 (06) 800-804
  CrossrefPubMedGoogle Scholar
• 15 McLaughlin VV, Benza RL, Rubin LJ. , et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010; 55 (18) 1915-1922
  CrossrefPubMedGoogle Scholar
• 16 Jing ZC, Parikh K, Pulido T. , et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation 2013; 127 (05) 624-633
  CrossrefPubMedGoogle Scholar
• 17 Barst RJ, McGoon M, McLaughlin V. , et al; Beraprost Study Group. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41 (12) 2119-2125
  CrossrefPubMedGoogle Scholar
• 18 Galiè N, Humbert M, Vachiéry JL. , et al; Arterial Pulmonary Hypertension and Beraprost European (ALPHABET) Study Group. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002; 39 (09) 1496-1502
  CrossrefPubMedGoogle Scholar
• 19 Olschewski H, Simonneau G, Galiè N. , et al; Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347 (05) 322-329
  CrossrefPubMedGoogle Scholar
• 20 Galiè N, Channick R, Chin K. , et al. Effect of selexipag on morbidity/mortality in pulmonary arterial hypertension: results of the GRIPHON study. J Am Coll Cardiol 2015; 34 (4, Suppl.): S163
  PubMedGoogle Scholar
• 21 Sitbon O, Channick R, Chin KM. , et al; GRIPHON Investigators. Selexipag for the treatment of pulmonary artery hypertension. N Engl J Med 2015; 373 (26) 2522-2533
  CrossrefPubMedGoogle Scholar
• 22 Dupuis J, Stewart DJ, Cernacek P, Gosselin G. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 1996; 94 (07) 1578-1584
  CrossrefPubMedGoogle Scholar
• 23 Clozel M, Breu V, Burri K. , et al. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 1993; 365 (6448): 759-761
  CrossrefPubMedGoogle Scholar
• 24 Galié N, Badesch D, Oudiz R. , et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46 (03) 529-535
  CrossrefPubMedGoogle Scholar
• 25 Iglarz M, Binkert C, Morrison K. , et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 2008; 327 (03) 736-745
  CrossrefPubMedGoogle Scholar
• 26 Pulido T, Adzerikho I, Channick RN. , et al; SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369 (09) 809-818
  CrossrefPubMedGoogle Scholar
• 27 Benedict N, Seybert A, Mathier MA. Evidence-based pharmacologic management of pulmonary arterial hypertension. Clin Ther 2007; 29 (10) 2134-2153
  CrossrefPubMedGoogle Scholar
• 28 Galiè N, Channick RN, Frantz RP. , et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J 2019; 53 (01) 1801889
  CrossrefPubMedGoogle Scholar
• 29 Spiekerkoetter E, Sung YK, Sudheendra D. , et al. Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension. Eur Respir J 2017; 50 (03) 1602449
  CrossrefPubMedGoogle Scholar
• 30 Komrokji R, Garcia-Manero G, Ades L. , et al. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. Lancet Haematol 2018; 5 (02) e63-e72
  PubMedGoogle Scholar
• 31 Boucherat O, Chabot S, Paulin R. , et al. HDAC6: a novel histone deacetylase implicated in pulmonary arterial hypertension. Sci Rep 2017; 7 (01) 4546
  CrossrefPubMedGoogle Scholar
• 32 Chun HJ, Bonnet S, Chan SY. Translational advances in the field of pulmonary hypertension. Translating microRNA biology in pulmonary hypertension. It will take more than “miR” words. Am J Respir Crit Care Med 2017; 195 (02) 167-178
  CrossrefPubMedGoogle Scholar
• 33 Meloche J, Pflieger A, Vaillancourt M. , et al. Role for DNA damage signaling in pulmonary arterial hypertension. Circulation 2014; 129 (07) 786-797
  CrossrefPubMedGoogle Scholar
• 34 Budas GR, Boehm M, Kojonazarov B. , et al. ASK1 inhibition halts disease progression in preclinical models of pulmonary arterial hypertension. Am J Respir Crit Care Med 2018; 197 (03) 373-385
  CrossrefPubMedGoogle Scholar
• 35 Lu HI, Huang TH, Sung PH. , et al. Administration of antioxidant peptide SS-31 attenuates transverse aortic constriction-induced pulmonary arterial hypertension in mice. Acta Pharmacol Sin 2016; 37 (05) 589-603
  CrossrefPubMedGoogle Scholar
• 36 Piao L, Fang YH, Cadete VJ. , et al. The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle. J Mol Med (Berl) 2010; 88 (01) 47-60
  PubMedGoogle Scholar
• 37 Hansmann G, de Jesus Perez VA, Alastalo TP. , et al. An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest 2008; 118 (05) 1846-1857
  CrossrefPubMedGoogle Scholar
• 38 Viethen T, Gerhardt F, Dumitrescu D. , et al. Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: a pilot study. Int J Cardiol 2014; 175 (02) 233-239
  CrossrefPubMedGoogle Scholar
• 39 Dahal BK, Cornitescu T, Tretyn A. , et al. Role of epidermal growth factor inhibition in experimental pulmonary hypertension. Am J Respir Crit Care Med 2010; 181 (02) 158-167
  CrossrefPubMedGoogle Scholar
• 40 Hoeper MM, Barst RJ, Bourge RC. , et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013; 127 (10) 1128-1138
  CrossrefPubMedGoogle Scholar
• 41 Mouchaers KT, Schalij I, de Boer MA. , et al. Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil. Eur Respir J 2010; 36 (04) 800-807
  CrossrefPubMedGoogle Scholar
• 42 Benza RL, Miller DP, Gomberg-Maitland M. , et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122 (02) 164-172
  CrossrefPubMedGoogle Scholar
• 43 Ghofrani HA, Al-Hiti H, Vonk-Noordegraaf A. , et al. Proof-of-concept study to investigate the efficacy, hemodynamics and tolerability of terguride vs. placebo in subjects with pulmonary arterial hypertension: results of a double blind, randomised, prospective phase IIa study. Am J Respir Crit Care Med 2012; 185: A2496
  PubMedGoogle Scholar
• 44 Said SI. Vasoactive intestinal peptide in pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 185 (07) 786 , author reply 786
  PubMedGoogle Scholar
• 45 van Campen JS, de Boer K, van de Veerdonk MC. , et al. Bisoprolol in idiopathic pulmonary arterial hypertension: an explorative study. Eur Respir J 2016; 48 (03) 787-796
  CrossrefPubMedGoogle Scholar
• 46 Tamura Y, Phan C, Tu L. , et al. Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension. J Clin Invest 2018; 128 (05) 1956-1970
  CrossrefPubMedGoogle Scholar
• 47 Diller GP, van Eijl S, Okonko DO. , et al. Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. Circulation 2008; 117 (23) 3020-3030
  CrossrefPubMedGoogle Scholar